Bei Liang Bio-Pharmaceutical (Shanghai) Co., Ltd.

Primary Objectives ◆ The rate of change (slope of growth rate) in geographic atrophy (GA) lesion size from baseline to month 24 assessed by fundus autofluorescence (FAF) imaging. Key Secondary Objectives ◆ To assess the best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart, measured from baseline to month 24 under standard illumination and low illumination conditions; ◆ To assess the area and size of the photoreceptor inner/outer segment junction (i.e., ellipsoid zone [EZ] lesions) from baseline to month 24 by spectral domain optical coherence tomography (SD-OCT); ◆ To assess the mean retinal thickness (i.e., outer, middle, and central zones) from baseline to month 24 by SD-OCT.

Primary objective: To evaluate the efficacy of Tinlarebant in slowing the growth rate of atrophic lesions in adolescent subjects with Stargardt disease type 1 (STGD1); Secondary objectives: To evaluate the efficacy secondary endpoint of Tinlarebant in adolescent subjects with STGD1 (secondary efficacy endpoint will be evaluated at 24 months); To evaluate the pharmacodynamics (PD) of Tinlarebant in adolescent subjects with STGD1; To evaluate the systemic and ocular safety and tolerability of Tinlarebant; Exploratory objectives: To evaluate the efficacy exploratory endpoint of Tinlarebant in adolescent subjects with STGD1.